British health regulator Medicines and Healthcare Products Regulatory Agency (MHRA), on Thursday, initiated recall of five prescription medicines of Wockhardt, following manufacturing deficiencies identified during an inspection of the companys site in Chikalthana in Maharashtra.
This follows a precautionary recall by Wockhardt, which is asking retail outlets to return five over-the-counter medicines, the MHRA said in a statement.
Ten prescription-only medicines can continue to be made at the Chikalthana site, and can still be supplied to patients in the U.K., the MHRA added.
This is because, due to concerns over the continuity of supply, the benefits to patients of continuing to take these medicines outweigh the risk from any quality concerns with the medicine, the MHRA said.
When contacted Wockhardt Chairman Habil Khorakiwala told PTI: We are moving forward to comply with MHRA requirements and we should be doing it quite soon.
Wockhardt in a filing to BSE said: The agency (MHRA) has issued a drug alert for recall of certain products, one time impact of which is expected to be approximately one million pounds. The MHRA said the medicines affected by the recall are in most cases available from alternative manufacturers.